• KOL
    • Penicillium Marneffei
    • Thira Sirisanthana
    • Thira Sirisanthana: Influence Statistics

      Thira Sirisanthana

      Thira Sirisanthana

      Show email address

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Thailand | Chiang Mai University Research Institute for Health Sciences Chiang Mai Thailand | Research ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Thira Sirisanthana:Expert Impact

      Concepts for whichThira Sirisanthanahas direct influence:Penicillium marneffei,Northern thailand,Antiretroviral therapy,Immune recovery,Marneffei infection,Primary prophylaxis,Infected children,Hivinfected children.

      Thira Sirisanthana:KOL impact

      Concepts related to the work of other authors for whichfor which Thira Sirisanthana has influence:Antiretroviral therapy,Penicillium marneffei,Hiv infection,Infected children,Rhodococcus equi,South africa,Scrub typhus.

      KOL Resume for Thira Sirisanthana

      Year
      2020

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Thailand

      2015

      Chiang Mai University Research Institute for Health Sciences Chiang Mai Thailand

      2013

      Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand

      2011

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

      Research Institute for Health Sciences, Chiang Mai

      2010

      From the *Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; †Chiang Mai Provincial Hospital, Chiang Mai, Thailand; and ‡Department of Pediatrics, Chiang Mai University, Chiang Mai, Thailand.

      PharmAccess Foundation, Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, National Centre in HIV Epidemiology and Clinical Research, UNSW, Sydney, Australia, School of Public Health and Community Medicine, UNSW, Sydney, Australia, Joint Clinical Research Center, Kampala, Uganda, HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand, Lusaka Trust Hospital, Lusaka, Zambia, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Themba Lethu Clinic, Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa, YRG Centre for AIDS Research and Education, Chennai, India, Muelmed Hospital, Pretoria, South Africa, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, International Center for Reproductive Health Kenya, Mombasa, Kenya, Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China, Newlands Clinic, Harare, Zimbabwe, Chiang Rai Regional Hospital, Chiang Rai, Thailand, Lagos University Teaching Hospital, Lagos, Nigeria, Hospital Sungai Buloh, Kuala Lumpur, Malaysia, Department of Molecular Medicine and Haematology, University of the Witwatersrand, and National Health Laboratory Services, Johannesburg, South Africa, University of Malaya, Kuala Lumpur, Malaysia, Department of Virology, University Medical Center, Utrecht, The Netherlands and, AIDS Prevention and Research Centre, National Yang-Ming University, Taipei, Taiwan

      2009

      Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, .

      2008

      Research Institute for Health Sciences, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

      2007

      From the *Research Institute for Health Sciences, †Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and ‡Ministry of Public Health, Bangkok, Thailand.

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

      2006

      From the *Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; †Sanpathong Hospital, Ministry of Public Health, Chiang Mai, Thailand; ‡the Faculty of Associated Medical Science, Chiang Mai University, Chiang Mai, Thailand; and §the Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.

      The Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand

      2005

      Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA

      Faculty of Medicine, Chiang Mai University, Chiang Mai, and Ministry of Public Health, Bangkok, Thailand

      2003

      From the Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

      Medicine, Faculty of Medicine, Chiang Mai University, and

      2001

      Chiang Mai University, Chiang Mai, Thailand.

      1999

      Medicine,3 Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

      1998

      Department of Medicine, Faculty of Medicine, Chiang Mai University Hospital, Chiang Mai, Thailand

      1997

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Thailand.

      1996

      Department of Microbiology, Faculty of Medicine, Chiang Mai University, Thailand.

      1995

      Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

      1994

      Faculty of Medicine, Chiang Mai University, Thailand.

      1985

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang mai, Thailand, .

      1983

      From the Departments of Pediatrics and Medicine Faculty of Medicine, Chiang Mai University, Chiang Mai 50000, Thailand.

      1979

      Department of Medicine (Infectious Disease), University of Chicago School of Medicine, Chicago, Illinois 60637

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Thira Sirisanthana is among the top experts in the world.
      Concept World rank
      olaarrrp detecting m184v #1
      arrrp #1
      central necrotic umbilication #1
      haart marneffei #1
      haart stavudine thailand #1
      monitoring yearly #1
      aids penicillium rats #1
      itraconazole primary prophylaxis #1
      marneffei cases #1
      substitution zidovudine #1
      revaccination mmr vaccine #1
      immune recovery haart #1
      growth reversal #1
      automatic hematoanalyzer #1
      wellstudied antibody responses #1
      patients marneffei #1
      mmr revaccination revaccination #1
      revaccination hivinfected children #1
      total 131 caregivers #1
      54 05 log10 #1
      positive immunoblot result #1
      protective antihbs level #1
      switch haemoglobin level #1
      types northern thailand #1
      multiple drugresistant virus #1
      1121 hivinfected children #1
      penicillium marneffei infection #1
      sevenyear time periods #1
      range common organisms #1
      virologic efficacy years #1
      finding isolates #1
      lipodystrophy switch #1
      resourcepoor setting initiation #1
      76 29 years #1
      virus human lectins #1
      cbc machine correlations #1
      central septation #1
      disseminated marneffei #1
      ld 144 weeks #1
      anthraxendemic areas #1
      longterm efficacy haart #1
      culture penicilliosis marneffei #1
      320 miu #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Thira Sirisanthana

      KOL-Index: 15077

      BACKGROUND: The low prevalence of measles antibody in human immunodeficiency virus (HIV)-infected children after immune recovery as a result of highly active antiretroviral therapy increases the risk of morbidity and mortality from disease. The objective of our study was to evaluate the efficacy and safety of revaccination with measles, mumps, and rubella (MMR) vaccine in HIV-infected children with immune recovery.

      METHODS: Inclusion criteria were (1) HIV-infected children aged >5 years, ...

      Known for Immune Recovery | Infected Children | Antiretroviral Therapy | Highly Active | Measles Mumps
      KOL-Index: 12273

      BACKGROUND: Programs for access to antiretroviral treatment were only recently implemented in developing countries. This study aimed to describe the effect of highly active antiretroviral therapy (HAART) in treating human immunodeficiency virus (HIV)-infected children in Thailand's National Access to Antiretroviral Program for People Living with HIV/AIDS.

      METHODS: From August 2002 to July 2003, a total of 107 children were enrolled in the study. They received HAART consisting of either ...

      Known for Highly Active | Antiretroviral Therapy | Hivinfected Children | Patients Hiv | Initiation Haart
      KOL-Index: 11888

      Mannoproteins are important and abundant structural components of fungal cell walls. The MP1 gene encodes a cell wall mannoprotein of the pathogenic fungus Penicillium marneffei. In the present study, we show that Mp1p is secreted into the cell culture supernatant at a level that can be detected by Western blotting. A sensitive enzyme-linked immunosorbent assay (ELISA) developed with antibodies against Mp1p was capable of detecting this protein from the cell culture supernatant of P. ...

      Known for Penicillium Marneffei | Cell Wall | Penicilliosis Patients | Culture Supernatants | Fungal Antigens
      KOL-Index: 11861

      BACKGROUND: Highly active antiretroviral therapy (HAART) has recently been implemented in Thailand. Its long-term effects have not been clearly evaluated. The objective of this study was to estimate the prevalence of lipodystrophy (LD) and other metabolic changes in HIV-infected children receiving HAART.

      METHODS: Ninety children who began HAART (either nevirapine or efavirenz, together with lamivudine and stavudine) were prospectively followed. LD was assessed by waist-to-hip ratio and ...

      Known for Antiretroviral Therapy | Prevalence Ld | Reverse Transcriptase | Highly Active | Low Hdl
      KOL-Index: 11812

      Despite a history of hepatitis B virus (HBV) vaccination prior to highly active antiretroviral therapy (HAART), most of HIV-infected children do not have protective antibody to HBV infection. The efficacy of an additional booster dose in children with immune recovery on HAART remains unknown. This study was conducted to determine the response rate of HBV antibody after re-vaccination in HIV-infected children with immune recovery on HAART. Sixty-three successfully HAART-treated ...

      Known for Immune Recovery | Antibody Response | Infected Children | Antiretroviral Therapy | Highly Active
      KOL-Index: 11094

      BACKGROUND: With the availability of highly active antiretroviral therapy, more HIV-infected children have lived longer. Many children are at the age that they should know the diagnosis.

      AIM: To identify the prevalence and patterns of disclosure of HIV/AIDS diagnosis to HIV-infected children.

      METHODS: A cross-sectional study was conducted among 103 main care givers of HIV-infected children aged > or =6 years who received highly active antiretroviral therapy at Chiang Mai University and ...

      Known for Children Diagnosis | Disclosure Hiv | Healthcare Providers | Antiretroviral Therapy | Highly Active
      KOL-Index: 10884

      BACKGROUND: Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with once-daily compared to twice-daily dosing in diverse areas of the world.

      METHODS AND FINDINGS: 1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned with equal probability to open-label antiretroviral therapy ...

      Known for Initial Treatment | Antiretroviral Regimens | Diverse Multinational Settings | Efficacy Safety | Randomized Clinical Trial
      KOL-Index: 10761

      BACKGROUND: There is little information about the immune reconstitution syndrome (IRS) in children, especially from resource-poor countries.

      OBJECTIVE: To determine the incidence and spectrum of IRS in advanced stage human immunodeficiency virus (HIV)-infected children after initiation of highly active antiretroviral therapy (HAART).

      METHODS: Between May 2002 and April 2004, 153 symptomatic HIV-infected children who had CD4 lymphocyte percentage < or =15% initiated HAART in a national ...

      Known for Highly Active | Immune Reconstitution Syndrome | Antiretroviral Therapy | Incidence Irs | Human Immunodeficiency
      KOL-Index: 10485

      BACKGROUND: Pediatric antiretroviral therapy programs have recently been implemented in resource-limited settings. Their impact in a prospective cohort is not well documented. The aim of this study was to evaluate the rates and causes of hospitalization and mortality among human immunodeficiency virus (HIV)-infected Thai children after receiving highly active antiretroviral therapy (HAART).

      METHODS: Children who started receiving HAART from August 2002 to March 2005 were prospectively ...

      Known for Highly Active | Infected Children | Antiretroviral Therapy | Studies Hiv | Haart Initiation
      KOL-Index: 9781

      Eighty-six patients with laboratory evidence of human immunodeficiency virus infection presented to Chiang Mai University Hospital in Chiang Mai, Thailand, between 1 June 1990 and 30 June 1992 with systemic infection caused by the dimorphic fungus Penicillium marneffei. Thirty isolates of P. marneffei from clinical specimens from these patients were tested for their in vitro susceptibilities to amphotericin B, 5-fluorocytosine, miconazole, ketoconazole, itraconazole, and fluconazole. P. ...

      Known for Penicillium Marneffei | Antifungal Therapy | Fluconazole Itraconazole | Clinical Specimens | Human Immunodeficiency
      KOL-Index: 9694

      BACKGROUND: Although patient attrition is recognized as a threat to the long-term success of antiretroviral therapy programs worldwide, there is no universal definition for classifying patients as lost to follow-up (LTFU). We analyzed data from health facilities across Africa, Asia, and Latin America to empirically determine a standard LTFU definition.

      METHODS AND FINDINGS: At a set "status classification" date, patients were categorized as either "active" or "LTFU" according to ...

      Known for Latin America | Hiv Treatment Programs | Patient Attrition | Health Facilities | Follow Ltfu
      KOL-Index: 9665

      Cryptococcal meningitis and Penicillium marneffei infection are common serious fungal infections in patients infected with human immunodeficiency virus (HIV) in Southeast Asia. In a prospective, double-blind trial, 63 patients with HIV infection and CD4+ lymphocyte counts of <200 cells/microL were randomized to receive oral itraconazole (200 mg per day), and 66 similar patients received a matched placebo. Both groups were monitored for evidence of invasive fungal infections. Baseline ...

      Known for Primary Prophylaxis | Controlled Trial | Human Immunodeficiency Virus | Cryptococcal Meningitis | Hiv Infection
      KOL-Index: 9629

      Penicillium marneffei has been described recently as a cause of an emerging mycotic infection in HIV-infected patients. A PCR/hybridization assay was developed to rapidly identify this pathogen. The nucleotide sequence of the 631-bp region of 18S ribosomal DNA of P. marneffei was determined using the standard dideoxy chain termination method. An oligonucleotide probe was designed on the basis of the analysed sequences of P. marneffei and 18S rDNA sequences of other fungi in the GenBank ...

      Known for Penicillium Marneffei | Fungal Rna | Polymerase Chain | Specific Identification | Dna Ribosomal
      KOL-Index: 9349

      Penicillium marneffei infection is an important emerging public health problem, especially among patients infected with human immunodeficiency virus in the areas of endemicity in southeast Asia, India, and China. Within these regions, P. marneffei infection is regarded as an AIDS-defining illness, and the severity of the disease depends on the immunological status of the infected individual. Early diagnosis by serologic and molecular assay-based methods have been developed and are ...

      Known for Marneffei Infection | Molecular Epidemiology | Rodents Humans | Southeast Asia | Early Diagnosis
      KOL-Index: 9117

      HIV-infected children had a lower seroconversion rate to hepatitis B immunization and a more rapid antibody decline when compared to healthy children. Whether re-immunization or additional booster dose is necessary after immune recovery remains unknown. This study was conducted to determine the prevalence of hepatitis B virus protective antibody in HIV-infected children with immune recovery after highly active antiretroviral therapy (HAART). Serum hepatitis B viral markers were measured. ...

      Known for Immune Recovery | Protective Antibody | Antiretroviral Therapy | Highly Active | Hivinfected Children

      Key People For Penicillium Marneffei

      Top KOLs in the world
      #1
      Thira Sirisanthana
      penicillium marneffei northern thailand antiretroviral therapy
      #2
      Khuanchai Supparatpinyo
      northern thailand penicillium marneffei human immunodeficiency virus
      #3
      Kenrad E Nelson†
      northern thailand hiv infection drug users
      #4
      Nongnuch Vanittanakom
      penicillium marneffei pythium insidiosum human pythiosis
      #5
      Chantana Khamwan
      penicillium marneffei cryptococcus neoformans serotype g9
      #6
      V Baosoung
      penicillium marneffei southeast asia opportunistic infections

      Department of Medicine, Faculty of Medicine, Chiang Mai University, Thailand | Chiang Mai University Research Institute for Health Sciences Chiang Mai Thailand | Research Institute for Health Sciences, Chiang Mai, Thailand, . | Research Institute for

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.